Browsing by Author "Akan, Hamdi"

Filter results by typing the first few letters
Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Diagnosis of invasive fungal diseases in hematological malignancies: A critical review of evidence and turkish expert opinion (teo-2)
    (Galenos Publ House, 2014-08-14) Akdağlı, Sevtap Arıkan; Azap, Alpay; Demirkazık, Figen Başaran; Hayran, Sibel Aşçıoğlu; Kumbasar, Özlem Özdemir; Metan, Gökhan; Odabaşı, Ekaver; Uzun, Ömrüm; Akan, Hamdi; Ener, Beyza; Uludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji Anabilim Dalı.; 0000-0002-4803-8206; AAG-8523-2021; 15053025300
    One of the most problematic issues in hematological malignancies is the diagnosis of invasive fungal diseases. Especially, the difficulty of mycological diagnosis and the necessity of immediate intervention in molds have led to the adoption of "surrogate markers" that do not verify but rather strongly suggest fungal infection. The markers commonly used are galactomannan (GM), beta-glucan, and imaging methods. Although there are numerous studies on these diagnostic approaches, none of these markers serve as a support for the clinician, as is the case in human immunodeficiency virus (HIV) or cytomegalovirus (CMV) infections. This paper has been prepared to explain the diagnostic tests. As molecular tests have not been standardized and are not used routinely in the clinics, they will not be mentioned here.
  • Thumbnail Image
    Item
    Recommendations for risk categorization and prophylaxis of invasive fungal diseases in hematological malignancies: A critical review of evidence and expert opinion (TEO-4)
    (Galenos Yayınları, 2015) Boğa, Can; Bolaman, Zahit; Çağırgan, Seçkin; Karadoğan, İhsan; Özcan, Mehmet Ali; Saba, Rabin; Sönmez, Mehmet; Şenol, Esin; Akan, Hamdi; Akova, Murat; Özkalemkaş, Fahir; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; AAG-8495-2021; 6601912387
    This is the last of a series of articles on invasive fungal infections prepared by opinion leaders in Turkey. The aim of these articles is to guide clinicians in managing invasive fungal diseases in hematological malignancies and stem cell transplantation based on the available best evidence in this field. The previous articles summarized the diagnosis and treatment of invasive fungal disease and this article aims to explain the risk categorization and guide the antifungal prophylaxis in invasive fungal disease.
  • Thumbnail Image
    Item
    Recommendations for the treatment of invasive fungal infections in hematological malignancies: A critical review of evidence and Turkish Expert Opinion (TEO-1)
    (Galenos Publ House, 2014-05-12) Akan, Hamdi; Öngören, Şeniz; Saltoğlu, Neşe; Çağatay, Arif Atahan; Arat, Mutlu Ersöz; Kalayoğlu, Sevgi B.; Demir, Ahmet Muzaffer; Akalın, Halis; Ali, Rıdvan; Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı.; AAU-8952-2020; 57207553671; 7201813027
    The introduction of novel antifungal agents for the treatment of invasive fungal disease in hematological malignancies and also changing treatment strategies have had a great impact in managing affected patients. The medical literature includes some important clinical studies that are being used as evidence for guidelines. The problem with these studies and the guidelines is that they are not very easy to interpret, they include controversial issues, and they are not easy to apply to every patient or country. This paper was designed to critically show the main problems associated with these approaches and provide important information that will help Turkish doctors to adopt them in daily clinical practice.
  • No Thumbnail Available
    Item
    Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: Results of a randomized multicenter phase III trial
    (Pergamon-Elsevier Science, 2011-03) Beksaç, Meral; Özcan, Muhit; Özçebe, Osman; Bayık, Mahmut; Paydaş, Semra; Büyükaşık, Yahya; İlhan, Osman; Gürman, Günhan; Uysal, Akın; Akan, Hamdi; Soydan, Ender Akcağlayan; Ali, Ridvan; Özçelik, Tülay; Özkalemkaş, Fahir; Tunalı, Ahmet; Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı.; AAG-8495-2021; 7201813027; 7005424333; 6601912387
    This prospective multicenter phase III clinical trial was designed to assess efficacy and safety of G-CSF as an adjunct to de novo AML remission induction therapy (www.clinicaltrials.gov.NCT00820976). Patients' characteristics were similar in both arms. G-CSF improved severity and duration of leukopenia. Three-year OS were similar (25.6 +/- 5.1% vs. 31.8 +/- 5.6%) in both arms except for patients with myeloblastic features. Significant factors for better survival were the use of G-CSF (p = 0.049), female sex (p = 0.05) and single induction cycle (p < 0.001) in multivariate analysis. Female patients performed better than male patients. Better survival obtained among female AML patients needs to be validated within the context of cytogenetic analysis.